OS-01 100mg / 30caps

p16INK4a, encoded by the CDKN2A locus, is a cyclin-dependent kinase inhibitor that suppresses CDK4/CDK6 activity, preventing retinoblastoma protein (Rb) phosphorylation and promoting cell-cycle arrest. It is one of the most widely utilized molecular markers of cellular senescence and is frequently employed as a readout in studies examining senescence-associated pathways, senescence burden, and cellular state transitions. Changes in p16INK4a expression are commonly used to evaluate the activity of compounds investigated for senolytic or senomorphic properties.

The senescence-associated secretory phenotype (SASP) is a collection of signaling molecules produced by senescent cells, including cytokines, chemokines, growth factors, proteases, and extracellular matrix-modifying enzymes. SASP-associated signaling can influence neighboring cells, alter local signaling environments, and modulate numerous downstream molecular pathways. Because SASP activity is considered a central feature of senescent cellular states, modulation of SASP-associated pathways has become a major area of investigation in cellular senescence research. Compounds that alter SASP output without eliminating senescent cells are commonly classified as senomorphic agents, whereas compounds that selectively remove senescent cells are classified as senolytics.

OS-01 is a short synthetic peptide investigated primarily for its effects on senescence-associated molecular pathways, p16INK4a-related regulatory mechanisms, and SASP-associated signaling networks. Unlike many established small-molecule senescence research compounds that target kinase signaling, apoptosis-regulatory pathways, or survival networks, OS-01 represents a peptide-based approach to senescence modulation. Its mechanism remains under active investigation, making it a useful research tool for studies exploring peptide-mediated regulation of senescence-associated processes, molecular aging pathways, and comparative senomodulatory pharmacology.